Subtype-dependent response of hepatitis B virus during the early phase of lamivudine treatment.
We conducted a 12-month longitudinal investigation of the subtype-dependent response of hepatitis B virus (HBV) to lamivudine treatment in 43 consecutive patients with chronic hepatitis B. HBV subtype ayw appears to respond better to lamivudine monotherapy than does HBV subtype adw (P=.005). This might be the reason for the lower incidence of lamivudine-resistant strains observed in persons infected with HBV subtype ayw during follow-up.
Zöllner
Bernhard
B
Institute for Medical Microbiology and Immunology, University Hospital Hamburg-Eppendorf, 20246 Hamburg, Germany. zoellner@uke.uni-hamburg.de
Petersen
Jörg
J
Schäfer
Peter
P
Schröter
Matthias
M
Laufs
Rainer
R
Sterneck
Martina
M
Feucht
Heinz-Hubert
HH
D000293:Adolescent; D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000627:therapeutic use*; D002648:Child; D005260:Female; D006515:Hepatitis B virus / Q000187:drug effects; D019694:Hepatitis B, Chronic / Q000188:drug therapy*; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use*; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome
D000998:Antiviral Agents; D019259:Lamivudine